Active	Status	Sponsor type	Region	Phase	Filter
7 Active 0 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Knowles, Lynne
UP-NEXT, NCT05329545: Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer	Terminated	3	20	Canada, US, RoW	Upifitimab rilsodotin, XMT-1536 Antibody Drug Conjugate, Placebo	Mersana Therapeutics, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)	High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer	09/23	09/23
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer	Recruiting	3	418	Europe, Canada, US, RoW	Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab	AbbVie, GOG Foundation	Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer	03/27	04/29
ZN-c3-004, NCT04814108: A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma	Recruiting	2	76	Canada, US, RoW	ZN-c3, azenosertib, KP-2638	K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc	Uterine Serous Carcinoma	11/24	05/25
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer	Completed	2	79	Europe, Canada, US, RoW	Mirvetuximab soravtansine, MIRV, IMGN853	AbbVie	Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer	01/24	12/24
ENGOT-ov60, NCT04625270 / 2020-004264-26: A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS Mutation	Active, not recruiting	2	225	Europe, Canada, US	avutometinib (VS-6766), avutometinib (VS-6766) and defactinib, avutometinib (VS-6766) and VS-6063	Verastem, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation	Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer	11/24	12/26
DENALI, NCT05128825: A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Active, not recruiting	2	102	Europe, US, RoW	ZN-c3, azenosertib	K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc	High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer	04/25	10/25
Paredes, Alfonzo
UP-NEXT, NCT05329545: Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer	Terminated	3	20	Canada, US, RoW	Upifitimab rilsodotin, XMT-1536 Antibody Drug Conjugate, Placebo	Mersana Therapeutics, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)	High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer	09/23	09/23